Last10K.com

Anika Therapeutics, Inc. (ANIK) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Anika Therapeutics, Inc.

CIK: 898437 Ticker: ANIK

Exhibit 99.1

Anika Reports Fourth Quarter and Full Year 2017 Financial Results

MONOVISC Global Revenue Increased 21% Year-over-Year for Fourth Quarter of 2017;
Total Revenue Increased 10% for Full Year of 2017

BEDFORD, Mass.--(BUSINESS WIRE)--February 21, 2018--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the fourth quarter and full year ended December 31, 2017, along with business progress in the periods.

“2017 was a year of significant achievement for Anika, highlighted by double-digit revenue growth, expansion of MONOVISC® and CINGAL® into new international markets, completion of the CINGAL Phase III trial enrollment ahead of schedule, and the strengthening of our executive team,” said Charles H. Sherwood, Ph.D., Chief Executive Officer. “As we look to 2018, we are poised to complete the CINGAL Phase III trial and submit a New Drug Application to the FDA. Our strategic objectives are focused on global commercial expansion, pipeline advancement, and the development of a direct commercialization capability in the U.S. to accelerate our revenue and earnings growth in the years ahead and to create sustained value for our shareholders.”


The following information was filed by Anika Therapeutics, Inc. (ANIK) on Wednesday, February 21, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Anika Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anika Therapeutics, Inc..

Continue

Assess how Anika Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anika Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Revenue
M & A
Other
Filter by Subcategory:
All
Earnings
Product
Shares
Expense
Cash Flow
Other
Inside Anika Therapeutics, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Note 18 - Quarterly Financial Data (unaudited)
Consolidated Balance Sheets
Consolidated Balance Sheets (parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Income
Consolidated Statements Of Stockholders' Equity
Note 1 - Nature Of Business
Note 10 - Accrued Expenses
Note 10 - Accrued Expenses (tables)
Note 10 - Accrued Expenses - Summary Of Accrued Expenses (details)
Note 11 - Commitments And Contingencies
Note 11 - Commitments And Contingencies (details Textual)
Note 11 - Commitments And Contingencies (tables)
Note 11 - Commitments And Contingencies - Future Lease Commitments (details)
Note 12 - Equity Incentive Plan
Note 12 - Equity Incentive Plan (details Textual)
Note 12 - Equity Incentive Plan (tables)
Note 12 - Equity Incentive Plan - Assumptions Used To Estimate Fair Value Of Stock Options And Stock Appreciation Rights (details)
Note 12 - Equity Incentive Plan - Restricted Stock Activity (details)
Note 12 - Equity Incentive Plan - Stock Options And Sar's Activity (details)
Note 12 - Equity Incentive Plan - Summary Of Exercisable Options And Sar's (details)
Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (details)
Note 13 - Employee Benefit Plan
Note 13 - Employee Benefit Plan (details Textual)
Note 14 - Shareholder Rights Plan
Note 14 - Shareholder Rights Plan (details Textual)
Note 15 - Revenue By Product Group, By Significant Customer And By Geographic Location; Geographic Information
Note 15 - Revenue By Product Group, By Significant Customer And By Geographic Location; Geographic Information (details Textual)
Note 15 - Revenue By Product Group, By Significant Customer And By Geographic Location; Geographic Information (tables)
Note 15 - Revenue By Product Group, By Significant Customer And By Geographic Region; Geographic Information - Net Tangible Long-lived Assets By Principal Geographic Areas (details)
Note 15 - Revenue By Product Group, By Significant Customer And By Geographic Region; Geographic Information - Product Revenue By Product Group (details)
Note 15 - Revenue By Product, By Significant Customer And By Geographic Region; Geographic Information - Total Revenue By Geographic Location (details)
Note 16 - Income Taxes
Note 16 - Income Taxes (details Textual)
Note 16 - Income Taxes (tables)
Note 16 - Income Taxes - Components Of Income Before Taxes And Provision For (benefit From) Income Taxes (details)
Note 16 - Income Taxes - Reconciliation Between U.s. Federal Statutory Rate And Effective Rate (details)
Note 16 - Income Taxes - Significant Components Of Company's Deferred Tax Assets And Liabilities (details)
Note 17 - Revolving Credit Agreement
Note 17 - Revolving Credit Agreement (details Textual)
Note 18 - Quarterly Financial Data (unaudited) (tables)
Note 18 - Quarterly Financial Data (unaudited) - Quarterly Financial Data (unaudited) (details)
Note 2 - Summary Of Significant Accounting Policies
Note 2 - Summary Of Significant Accounting Policies (details Textual)
Note 2 - Summary Of Significant Accounting Policies (tables)
Note 2 - Summary Of Significant Accounting Policies - Allowance For Doubtful Accounts (details)
Note 2 - Summary Of Significant Accounting Policies - Estimated Useful Lives Of Property And Equipment (details)
Note 3 - Investments
Note 3 - Investments (details Textual)
Note 4 - Fair Value Measurements
Note 4 - Fair Value Measurements (tables)
Note 4 - Fair Value Measurements - Fair Value Of Financial Instruments (details)
Note 5 - Earnings Per Share ("eps")
Note 5 - Earnings Per Share ("eps") (details Textual)
Note 5 - Earnings Per Share ("eps") (tables)
Note 5 - Earnings Per Share ("eps") - Basic And Diluted Earnings Per Share (details)
Note 6 - Inventories
Note 6 - Inventories (tables)
Note 6 - Inventories - Summary Of Inventories (details)
Note 7 - Property And Equipment
Note 7 - Property And Equipment (details Textual)
Note 7 - Property And Equipment (tables)
Note 7 - Property And Equipment - Property And Equipment At Cost (details)
Note 8 - Acquired Intangible Assets, Net
Note 8 - Acquired Intangible Assets, Net (details Textual)
Note 8 - Acquired Intangible Assets, Net (tables)
Note 8 - Intangible Assets - Summary Of Intangible Assets (details)
Note 9 - Goodwill
Note 9 - Goodwill (tables)
Note 9 - Goodwill - Changes In The Carrying Value Of Goodwill (details)
Significant Accounting Policies (policies)
Ticker: ANIK
CIK: 898437
Form Type: 10-K Annual Report
Accession Number: 0001171843-18-001450
Submitted to the SEC: Mon Feb 26 2018 9:13:01 PM EST
Accepted by the SEC: Tue Feb 27 2018
Period: Sunday, December 31, 2017
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anik/0001171843-18-001450.htm